Azienda Sanitaria Locale Cn2 Alba-Bra

At Azienda Sanitaria Locale Cn2 Alba-Bra, the clinical research program is centered on oncology, with a smaller but important focus on cancer-associated thrombosis. The studies explore several major cancers, including prostate cancer, ovarian cancer, cervical cancer, and urothelial cancer, while also addressing venous thromboembolism in people living with cancer. Overall, the trials are aimed at improving treatment effectiveness, reducing recurrence, and refining supportive care.

• Prostate cancer research includes approaches for metastatic castration-resistant disease and hormone-sensitive metastatic disease, testing ways to improve disease control and survival.
• Cervical cancer studies examine whether HPV vaccination before surgery can lower the risk of disease coming back.
• Ovarian cancer and urothelial cancer trials are focused on evaluating maintenance and targeted treatment strategies to delay progression.
• Colorectal cancer research is assessing the best first-line treatment choice for patients with metastatic disease.
• Venous thromboembolism studies in patients with cancer are comparing options to prevent clot recurrence more effectively and safely.

The site’s work reflects a strong interest in personalized cancer therapy, including targeted treatment selection, combination strategies, and supportive interventions that may improve outcomes for patients treated at this hospital/clinic.

A major part of the research at this site involves genitourinary cancers and gynecologic malignancies. Investigators are studying advanced forms of prostate cancer, including metastatic castration-resistant prostate cancer and oligometastatic hormone-sensitive prostate cancer, as well as ovarian cancer and cervical cancer. These trials aim to improve survival, delay progression, and reduce the chance of recurrence after local or systemic treatment.

• Metastatic prostate cancer studies are testing whether adding local radiation or changing systemic treatment can improve biochemical response and progression-free survival.
• Ovarian cancer research is evaluating whether maintenance treatment can keep disease under control for longer after initial chemotherapy.
• Cervical cancer work is focused on preventing post-surgical recurrence through HPV-related prevention strategies.
• Urothelial cancer trials assess treatment options for patients whose disease has already responded to platinum-based therapy.

This area of research highlights a practical focus on better disease management for patients with solid tumors, especially where long-term control and recurrence prevention are key goals.

The site is also involved in studies that compare different targeted therapies and combination regimens for difficult-to-treat cancers. These trials are designed to identify which treatment approaches offer the best control of advanced disease, especially in patients whose tumors have specific molecular features or have stopped responding to earlier therapy.

• In metastatic colorectal cancer, researchers are comparing two widely used biologic treatment strategies to see which better delays disease progression.
• In prostate cancer, trials are evaluating whether chemotherapy or androgen receptor-targeted treatment performs better in selected patients.
• Biomarker-driven oncology is a recurring theme, with studies guided by tumor characteristics such as BRCA status and cyclin E1 overexpression.
• These projects aim to refine treatment selection and improve outcomes through more personalized care.

The research portfolio at Azienda Sanitaria Locale Cn2 Alba-Bra shows a clear commitment to advancing precision oncology through comparative studies that may help match patients with the most effective therapy.

Beyond tumor-directed therapy, the site contributes to research on cancer-associated venous thromboembolism, an important complication that can affect treatment safety and quality of life. These studies focus on preventing clot recurrence in patients with active cancer, while also considering bleeding risk and overall tolerability.

• Venous thromboembolism trials are comparing anticoagulation strategies in people with cancer and recent clotting events.
• The goal is to find safer and more effective ways to reduce repeat events during ongoing cancer care.
• This work supports the broader management of patients with advanced malignancies who need both anticancer therapy and careful complication prevention.

By including this area alongside its oncology studies, the site addresses both treatment effectiveness and the everyday clinical challenges that can influence patient outcomes.